Cannabis users reported that it can reduce the symptoms of inflammatory bowel disease (IBD). Ultimately for the first time, this statement was proven by an experiment conducted in mice jointly by the University of Bath and the University of Massachusetts Medical School. The research findings were published in the Journal of Clinical Investigation.
Findings from a study conducted by Prof. Marco Falasca from Queen Mary University of London (QMUL) in the United Kingdom and team on a mouse model of pancreatic cancer, which they injected with cannabidiol (CBD), naturally occurring cannabis along with a classic chemotherapy drug, Gemcitabine, revealed that the rodents lived almost three times more than mice from a control group, which had been treated with Gemcitabine only.
Epidiolex, compounded from decontaminated cannabidiol, or CBD, permitted for two atypical types of epilepsy, would be the first prescription medication extracted from the marijuana plant, expected to reach pharmacies this fall.
Epidiolex, also known as purified cannabidiol was approved to treat Lennox-Gastaut syndrome and Dravet syndrome specifically in patients aged 2 and older. Both these conditions start during childhood. Recurrent seizures pose a huge risk of death.
The issue gained widespread public attention following the application by a boy’s family suffering from a rare form of epilepsy to use cannabis oil medication. The Home Secretary stated that a license would be issued for the boy’s treatment procedure to go ahead.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.